我要投票 仙琚制药在中草药行业中的票数:918
· 外 推 电 报 ·
2026-01-08 09:56:28 星期四

【仙琚制药是哪个国家的品牌?】

仙琚制药是什么牌子?「仙琚制药」是 浙江仙琚制药股份有限公司 旗下著名品牌。该品牌发源于浙江,由创始人张宇松在2000期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力仙琚制药品牌出海!将品牌入驻外推网,定制仙琚制药品牌推广信息,可以显著提高仙琚制药产品曝光,简直是跨境电商爆单神器!目前仅需1000元/年哦~

浙江仙琚制药股份有限公司前身为仙居制药厂,创建于1972年,是国内规模最大、品种最为齐全的甾体药物生产厂家,是国家计划生育药物定点生产厂家、国家火炬计划重点高新技术企业、全国守合同重信用企业、浙江省优秀创新型单位。公司总股本34140万元,占地面积337607平方米,现有员工2000多人,其中工程技术人员占30%,销售人员占36%,是原料药和制剂综合生产厂家。

公司产品独树一帜,主营业务为甾体原料药和制剂的研制、生产与销售。主要生产皮质激素类药物、性激素类药物(妇科及计生用药)和麻醉与肌松类药物三大类。共有近100多个品种。拥有200吨原料药、70亿片片剂、5亿粒胶囊、2亿支水针、1000万支冻干粉针剂、1000万支乳膏剂、1000万袋颗粒剂的生产能力。

公司与中国科学院上海有机所、中国药科大学等20多个国内着名科研院(校),建立了长期的合作关系,并投资建立了浙江仙琚制药技术开发有限公司。近几年,成功地开发了20多个高科技新药品种,取得了近30余项省级以上科研成果。公司的维库溴铵及其制剂(仙林)、米非司酮片(含珠停)与胶囊、复方戊酸雌二醇片、匹多莫德及其制剂等22个产品为国家级新药;维库溴铵及其注射剂项目、匹多莫德原药及颗粒制项目和糠酸莫米松及乳膏项目被列入国家级火炬计划项目;醋酸烯诺酮及其一根型皮下埋植剂被列入"十五"国家科技攻关项目;抗早孕一类新药ZXH951项目列入国家863计划。地塞米松系列产品的"绿色生产技术与示范"列入国家科技支撑计划(获得的国家资助与"863"项目相当);甲基泼尼松龙为浙江省重大科技攻关项目。抗早孕药物"含珠停"和肌松药物"仙林"是浙江名牌产品。

截止目前,公司已拥有6项专利发明。公司已在6个国家和地区总计23种产品取得了国际认证,其中,泼尼松龙、醋酸泼尼松、醋酸甲羟孕酮、维库溴铵等四个产品通过美国FDA认证。泼尼松龙、醋酸环丙孕酮等两个产品获得法国GMP证书。泼尼松龙通过欧洲COS和韩国KFDA认证。全部产品均已通过国家GMP认证。

公司拥有一支超过700人的制剂产品销售队伍,形成了医院线和OTC线两个完整的销售网络,并摸索出了有效的销售管理和市场推广策略。公司医院线的销售网络已覆盖全国地级市以上的主要医院,与2800多家医院的妇产科和3500多家医院的麻醉科建立了业务联系;OTC线的销售人员管理的药店已达到6万多家。公司国际贸易部已与美国、印度、英国等30多个国家的40多家原料药加工企业、制剂生产厂家和贸易商建立了业务联系。

目前,公司控股和投资了浙江仙居制药销售有限公司等企业。2010年1月12日,公司已正式在深交所挂牌交易,成功登陆资本市场。为实现规模经营,公司分别在浙江省化学原料药基地及仙居工业园区共征地面积254119平方米,作为原料药新产品生产基地。

未来的五年中,公司总体战略将以营销为导向,"先做强后做大",提升核心竞争力,在提高盈利能力的前提下扩大销售规模。

英文翻译:Zhejiang Xianju Pharmaceutical Co., Ltd., formerly known as Xianju pharmaceutical factory, was founded in 1972. It is the largest and most complete steroid drug manufacturer in China. It is a designated manufacturer of national family planning drugs, a key high-tech enterprise under the national Torch Program, a national contract abiding and trustworthy enterprise, and an excellent innovative unit in Zhejiang Province. The company has a total capital of 341.4 million yuan, covers an area of 337607 square meters, and has more than 2000 employees, including 30% of engineering and technical personnel and 36% of sales personnel. It is a comprehensive manufacturer of APIs and preparations. The company's products are unique, and its main business is the research, production and sales of steroid APIs and preparations. It mainly produces corticosteroids, sex hormones (gynecological and family planning drugs) and anesthetics and muscle pines. There are more than 100 varieties. It has a production capacity of 200 tons of APIs, 7 billion tablets, 500 million capsules, 200 million water needles, 10 million freeze-dried powder injections, 10 million cream and 10 million bags of granules. The company has established long-term cooperative relations with more than 20 famous domestic scientific research institutes (universities) such as Shanghai Institute of organic science, Chinese Academy of Sciences and China Pharmaceutical University, and invested in the establishment of Zhejiang Xianju Pharmaceutical Technology Development Co., Ltd. In recent years, more than 20 high-tech new drug varieties have been successfully developed and more than 30 scientific research achievements at or above the provincial level have been achieved. 22 products of the company, including vecuronium and its preparation (Xianlin), mifepristone tablet (including Zhuting) and capsule, compound estradiol valerate tablet, pidomode and its preparation, are national new drugs; vecuronium and its injection project, pidomode technical product and granule production project, mometasone furoate and cream project are listed in the national torch program project; enolone acetate and one of its products The project of zxh951, a new drug against early pregnancy, was listed in the National 863 program. The "green production technology and demonstration" of dexamethasone series products are listed in the national science and technology support plan (the national funding is equivalent to the "863" project); methylprednisolone is a major science and technology research project in Zhejiang Province. "Hanzhuting", an anti early pregnancy drug, and "Xianlin", a muscle relaxant, are famous brands in Zhejiang Province. Up to now, the company has 6 patent inventions. The company has obtained international certification for 23 kinds of products in 6 countries and regions, including prednisolone, prednisone acetate, medroxyprogesterone acetate, vecuronium and other four products which have passed FDA certification. Prednisolone, cyproterone acetate and other two products obtained the French GMP certificate. Prednisolone is certified by European COS and Korean KFDA. All products have passed the national GMP certification. The company has a sales team of more than 700 pharmaceutical products, formed two complete sales networks of hospital line and OTC line, and explored effective sales management and marketing strategies. The sales network of the company's hospital line has covered major hospitals at prefecture level and above in China, and established business contacts with the gynecology and obstetrics departments of more than 2800 hospitals and the anesthesiology departments of more than 3500 hospitals; the sales staff of OTC line has managed more than 60000 pharmacies. The International Trade Department of the company has established business contacts with more than 40 API processing enterprises, preparation manufacturers and traders in more than 30 countries, such as the United States, India and the United Kingdom. At present, the company holds and invests in such enterprises as Zhejiang Xianju Pharmaceutical Sales Co., Ltd. On January 12, 2010, the company was officially listed on the Shenzhen Stock Exchange and successfully landed in the capital market. In order to achieve large-scale operation, the company has acquired 25419 square meters of land in Zhejiang chemical API base and Xianju Industrial Park respectively as the production base of new API products. In the next five years, the company's overall strategy will be guided by marketing, "strengthen first and then expand", enhance core competitiveness, and expand sales scale on the premise of improving profitability.

本文链接: https://www.waitui.com/brand/e01e6332a.html 联系电话:请联系客服添加 联系邮箱:请联系客服添加

外推网广告位招租,每天只要9块9

7×24h 快讯

具身机器人也有自己的保单,险企竞逐机器人保险业务

机器人租赁市场需求旺盛,也催生了大量的保险保障需求。多位业内人士认为,机器人保险作为新型保险产品,其发展成熟需要大量的数据支撑,如果仅与单一企业合作或投保单一设备,数据积累会比较慢。通过与租赁平台等合作,不仅可以获得批量保单,也有利于实现数据的快速积累,为精算定价、风险理赔提供数据支撑,机器人保险有望迎来新增长极。不过,机器人保险在我国还处在起步阶段,发展过程中的风险评估难、产品适配差、责任界定难、风控能力弱等问题,还需要多方协作、共同破局。(上证报)

2小时前

日本11月份实际工资同比下降2.8%,为去年1月以来最大降幅

日本政府周四公布的初步数据显示,受一次性奖金大幅减少的拖累,日本11月份实际工资出现了自去年1月以来的最大降幅。与此同时,通胀超过工资增长的潜在趋势没有改变,这给日本央行带来了挑战。此前日本央行已发出信号,将在今年继续加息。(新浪财经)

2小时前

机构称2026年铜市上行趋势明朗

2025年年末,国内铜现货(电解铜)价格突破100000元/吨关口,为铜市注入强劲动力。与此同时,2026年长单签订博弈进入白热化,国内提价潮、外贸溢价攀升、铜精矿加工费(TC/RC)低位僵持等现象集中出现。业内人士表示,这既反映出市场对供需格局的预判,也预示着2026年铜价或开启新一轮上涨行情。(中证网)

2小时前

中信建投:商业航天产业有望进入新纪元

36氪获悉,中信建投指出,当前商业航天产业在国家政策支持和产业技术突破共同助力下,有望进入新纪元。商业航天产业涉及信息化的主要环节包括(1)遥感及其应用;(2)卫星测运控系统;(3)CAE仿真/卫星测试;(4)星际传输处理模块、通信模组、数据处理平台等;新场景扩展层面关注太空算力。此外,我们认为当前商业航天发展是国企与民营企业共振周期。

2小时前

耐心资本布局硬科技,社保科创基金多地落子

长期资本正在重塑科技创新领域的投资生态。全国社会保障基金理事会官网显示,目前已成立的5只社保科创基金定位均为“服务国家发展的市场化基金”,旨在疏通金融资源进入实体经济的渠道,增加支持科技创新和产业创新深度融合的有效投资,在服务科技强国建设、助力科创企业成长中实现基金安全和保值增值。多位专家介绍,从浙江首发到江苏、福建、湖北、四川相继跟进,社保科创基金的迅速布局,标志着国家长期、耐心资本与区域创新战略的系统性对接已进入加速布局阶段。(上证报)

2小时前

本页详细列出关于仙琚制药的品牌信息,含品牌所属公司介绍,仙琚制药所处行业的品牌地位及优势。
咨询